Cargando…
Dosimetric advantage of volumetric modulated arc therapy in the treatment of intraocular cancer
OBJECTIVE: The purpose of this study is to investigate the dosimetric advantages of volumetric modulated arc therapy (VMAT) in the treatment of intraocular cancer by comparing it directly with three-dimensional conformal radiotherapy (CRT) and intensity-modulated radiotherapy (IMRT). METHODS: CRT pl...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424493/ https://www.ncbi.nlm.nih.gov/pubmed/28490344 http://dx.doi.org/10.1186/s13014-017-0819-7 |
_version_ | 1783235148456656896 |
---|---|
author | Deng, Zhenxiang Shen, Lanxiao Zheng, Xiaomin Zhou, Yongqiang Yi, Jinling Han, Ce Xie, Congying Jin, Xiance |
author_facet | Deng, Zhenxiang Shen, Lanxiao Zheng, Xiaomin Zhou, Yongqiang Yi, Jinling Han, Ce Xie, Congying Jin, Xiance |
author_sort | Deng, Zhenxiang |
collection | PubMed |
description | OBJECTIVE: The purpose of this study is to investigate the dosimetric advantages of volumetric modulated arc therapy (VMAT) in the treatment of intraocular cancer by comparing it directly with three-dimensional conformal radiotherapy (CRT) and intensity-modulated radiotherapy (IMRT). METHODS: CRT plan, 7f-IMRT plan, and one-arc VMAT plan were generated for 14 intraocular cancer patients. Dosimetric and biological quality indices for target volume and organs at risks (OARs) were evaluated and compared. RESULTS: The target coverage presented by V95 for CRT, IMRT and VMAT were 95.02% ± 0.67%, 95.51% ± 2.25%, and 95.92% ± 3.05%, respectively. The homogeneity index (HI) for CRT, IMRT and VMAT were 0.15 ± 0.05, 0.23 ± 0.05, and 0.23 ± 0.06, respectively. IMRT and VMAT greatly decreased the dose to ipsilateral lens compared with CRT with a D1 of 2972.66 ± 1407.12 cGy, 3317.82 ± 915.28 cGy and 4809.54 ± 524.60 cGy for IMRT, VMAT and CRT, respectively. Similar results were observed for ipsilateral eyeballs. IMRT and VMAT also spared better on brainstem, optical nerves and optical chiasm compared CRT. However, CRT achieved lower dose to the eyeballs compared with IMRT and VMAT. VMAT and IMRT showed mixed results on target coverage and OAR sparing. The average MUs and delivery time of IMRT and VMAT were 531.25 ± 81.21 vs. 400.99 ± 61.49 and 5.05 ± 0.53 vs.1.71 ± 0.69 min, respectively. CONCLUSIONS: Although no clear distinction on PTV coverage among CRT, IMRT and VMAT plans was observed in the treatment of intraocular cancer, VMAT and IMRT achieved better homogeneity and conformity for target volume, and delivered fewer doses to ipsilateral lens and eyeballs compared with CRT. However, VMAT and IMRT increased the low dose volume to the contralateral OARs. Although VMAT and IMRT showed mixed results on target coverage and OAR sparing, VMAT decreased MU and delivery time significantly compared with IMRT. VMAT is a promising and feasible external beam radiotherapy technique in the treatment of intraocular cancer patients. |
format | Online Article Text |
id | pubmed-5424493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54244932017-05-11 Dosimetric advantage of volumetric modulated arc therapy in the treatment of intraocular cancer Deng, Zhenxiang Shen, Lanxiao Zheng, Xiaomin Zhou, Yongqiang Yi, Jinling Han, Ce Xie, Congying Jin, Xiance Radiat Oncol Research OBJECTIVE: The purpose of this study is to investigate the dosimetric advantages of volumetric modulated arc therapy (VMAT) in the treatment of intraocular cancer by comparing it directly with three-dimensional conformal radiotherapy (CRT) and intensity-modulated radiotherapy (IMRT). METHODS: CRT plan, 7f-IMRT plan, and one-arc VMAT plan were generated for 14 intraocular cancer patients. Dosimetric and biological quality indices for target volume and organs at risks (OARs) were evaluated and compared. RESULTS: The target coverage presented by V95 for CRT, IMRT and VMAT were 95.02% ± 0.67%, 95.51% ± 2.25%, and 95.92% ± 3.05%, respectively. The homogeneity index (HI) for CRT, IMRT and VMAT were 0.15 ± 0.05, 0.23 ± 0.05, and 0.23 ± 0.06, respectively. IMRT and VMAT greatly decreased the dose to ipsilateral lens compared with CRT with a D1 of 2972.66 ± 1407.12 cGy, 3317.82 ± 915.28 cGy and 4809.54 ± 524.60 cGy for IMRT, VMAT and CRT, respectively. Similar results were observed for ipsilateral eyeballs. IMRT and VMAT also spared better on brainstem, optical nerves and optical chiasm compared CRT. However, CRT achieved lower dose to the eyeballs compared with IMRT and VMAT. VMAT and IMRT showed mixed results on target coverage and OAR sparing. The average MUs and delivery time of IMRT and VMAT were 531.25 ± 81.21 vs. 400.99 ± 61.49 and 5.05 ± 0.53 vs.1.71 ± 0.69 min, respectively. CONCLUSIONS: Although no clear distinction on PTV coverage among CRT, IMRT and VMAT plans was observed in the treatment of intraocular cancer, VMAT and IMRT achieved better homogeneity and conformity for target volume, and delivered fewer doses to ipsilateral lens and eyeballs compared with CRT. However, VMAT and IMRT increased the low dose volume to the contralateral OARs. Although VMAT and IMRT showed mixed results on target coverage and OAR sparing, VMAT decreased MU and delivery time significantly compared with IMRT. VMAT is a promising and feasible external beam radiotherapy technique in the treatment of intraocular cancer patients. BioMed Central 2017-05-10 /pmc/articles/PMC5424493/ /pubmed/28490344 http://dx.doi.org/10.1186/s13014-017-0819-7 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Deng, Zhenxiang Shen, Lanxiao Zheng, Xiaomin Zhou, Yongqiang Yi, Jinling Han, Ce Xie, Congying Jin, Xiance Dosimetric advantage of volumetric modulated arc therapy in the treatment of intraocular cancer |
title | Dosimetric advantage of volumetric modulated arc therapy in the treatment of intraocular cancer |
title_full | Dosimetric advantage of volumetric modulated arc therapy in the treatment of intraocular cancer |
title_fullStr | Dosimetric advantage of volumetric modulated arc therapy in the treatment of intraocular cancer |
title_full_unstemmed | Dosimetric advantage of volumetric modulated arc therapy in the treatment of intraocular cancer |
title_short | Dosimetric advantage of volumetric modulated arc therapy in the treatment of intraocular cancer |
title_sort | dosimetric advantage of volumetric modulated arc therapy in the treatment of intraocular cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424493/ https://www.ncbi.nlm.nih.gov/pubmed/28490344 http://dx.doi.org/10.1186/s13014-017-0819-7 |
work_keys_str_mv | AT dengzhenxiang dosimetricadvantageofvolumetricmodulatedarctherapyinthetreatmentofintraocularcancer AT shenlanxiao dosimetricadvantageofvolumetricmodulatedarctherapyinthetreatmentofintraocularcancer AT zhengxiaomin dosimetricadvantageofvolumetricmodulatedarctherapyinthetreatmentofintraocularcancer AT zhouyongqiang dosimetricadvantageofvolumetricmodulatedarctherapyinthetreatmentofintraocularcancer AT yijinling dosimetricadvantageofvolumetricmodulatedarctherapyinthetreatmentofintraocularcancer AT hance dosimetricadvantageofvolumetricmodulatedarctherapyinthetreatmentofintraocularcancer AT xiecongying dosimetricadvantageofvolumetricmodulatedarctherapyinthetreatmentofintraocularcancer AT jinxiance dosimetricadvantageofvolumetricmodulatedarctherapyinthetreatmentofintraocularcancer |